Filled with a total of 16 different beauty buys, the box features popular brands for a fraction of the price
Boots has launched its popular £55 beauty box which can save shoppers a whopping £145 on premium beauty products.
For those into their glowy skincare, this highly anticipated limited-edition box proves popular every year, and now it's back. . The newest Boots beauty box features products guaranteed to give you that summer glow. There will be five-full sized products including the Elemis Superfood Glow Priming Moisturiser, the Fenty Skin Buff Ryder Exfoliating Body Scrub, and much more.Popular high street retailer Boots is known for its huge savings on beauty boxes. It recently released a £50 Love Island beauty box, containing £267 worth of products - which is currently sold out.
On the Boots website, the description reads: "For you glow getters! Our Summer Glow Beauty Box is full of key beauty essentials that you shouldn't be without this summer! Get a healthy glow and feel your best this summer and beyond with a wonderful selection of must have skin and body care essentials.
What's in the Boots Summer Glow Beauty Box? You can purchase Boots' latest summer beauty box for £55 here.For more Shopping Reviews and top deals sign up to our free newsletter.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Boots launches summer beauty box selling £200 worth of products for just £55The unmissable collection, which includes products from top brands such as Sol de Janeiro and Elemis, is only available for a limited time.
Read more »
From Tabis To £2K Teletubby Boots, This Instagram Account Revisits The Most Outré Shoes In Fashion HistorySee: Christian Louboutin’s lion paw heels.
Read more »
'I went to Tennessee - now I love steakhouses and country music'It's time to dig out those cowboy boots and get ready to feel like a true Southern Belle as we explore a real adventure in one of America's most southern states
Read more »
Doja Cat wows fans in glittering lingerie as she poses for Victoria's SecretDOJA Cat has got the cream. The US rapper, 27, is all sheer and sparkles as she poses for Victoria’s Secret. As well as glittering lingerie, Doja wears lace up golden boots and a nude PVC trench co…
Read more »
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study - Cardiovascular DiabetologyBackground Sodium-glucose co-transporter-2 inhibitors displayed cardiovascular benefits in type 2 diabetes mellitus in previous studies; however, there were some heterogeneities regarding respective cardiovascular outcomes within the class. Furthermore, their efficacies in Asians, females, and those with low cardiovascular risks were under-represented. Thus, we compared the cardiovascular outcomes between new users of dapagliflozin and empagliflozin in a broad range of patients with type 2 diabetes mellitus using a nationwide population-based real-world cohort from Korea. Methods Korean National Health Insurance registry data between May 2016 and December 2018 were extracted, and an active-comparator new-user design was applied. The primary outcome was a composite of heart failure (HF)-related events (i.e., hospitalization for HF and HF-related death), myocardial infarction, ischemic stroke, and cardiovascular death. The secondary outcomes were individual components of the primary outcome. Results A total of 366,031 new users of dapagliflozin or empagliflozin were identified. After 1:1 nearest-neighbor propensity score matching, 72,752 individuals (mean age approximately 56 years, 42% women) from each group were included in the final analysis, with a follow-up of 150,000 ~ person-years. Approximately 40% of the patients included in the study had type 2 diabetes mellitus as their sole cardiovascular risk factor, with no other risk factors. The risk of the primary outcome was not different significantly between dapagliflozin and empagliflozin users (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.855–1.006). The risks of secondary outcomes were also similar, with the exception of the risks of HF-related events (HR 0.84, 95% CI 0.714–0.989) and cardiovascular death (HR 0.76, 95% CI 0.618–0.921), which were significantly lower in the dapagliflozin users. Conclusions This large-scale nationwide population-based real-world cohort study revealed no significant diffe
Read more »
Boots launches summer beauty box selling £200 worth of products for just £55The unmissable collection, which includes products from top brands such as Sol de Janeiro and Elemis, is only available for a limited time.
Read more »